Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01783522 · OUTCOME

Adherence to Bortezomib Treatment

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib · Source last updated 2019-10-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
% of doses taken
Interval / dispersion
Not reported
Time frame
Up to 4 months

What was measured

Adherence reported as a percentage based on number of doses of study drug taken divided by the expected number of doses of study drug expected to be taken for the study duration.

Analysis population: All patients enrolled in study and given treatment

Groups in this outcome

Arm I (Preventative Nutritional Supplementation)

Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity. glutamine: Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months. quality-of-life assessment: Ancillary studies

Arm II (Placebo)

Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity. quality-of-life assessment: Ancillary studies placebo: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Preventative Nutritional Supplementation)4
Arm II (Placebo)5

Reported measurements

Source class 1
Values in % of doses taken · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm I (Preventative Nutritional Supplementation)100Not reportedNot reportedNot reportedNot reported
Arm II (Placebo)98.2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        100
      2. group Id
        OG001
        value
        98.2
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      5
    units
    Participants
description
Adherence reported as a percentage based on number of doses of study drug taken divided by the expected number of doses of study drug expected to be taken for the study duration.
groups
  1. description
    Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity. glutamine: Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months. quality-of-life assessment: Ancillary studies
    id
    OG000
    title
    Arm I (Preventative Nutritional Supplementation)
  2. description
    Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity. quality-of-life assessment: Ancillary studies placebo: Given PO
    id
    OG001
    title
    Arm II (Placebo)
param Type
NUMBER
population Description
All patients enrolled in study and given treatment
reporting Status
POSTED
time Frame
Up to 4 months
title
Adherence to Bortezomib Treatment
type
SECONDARY
unit Of Measure
% of doses taken

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice